RCS - Arecor Therapeutics - Arecor to present on Investor Meet Company

Arecor TherapeuticsAnnouncement

27/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240927:nRSa9019Fa&default-theme=true

RNS Number : 9019F  Arecor Therapeutics PLC  27 September 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

Arecor to present on Investor Meet Company platform

 

Cambridge, UK, 27 September 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that Sarah Howell, Chief Executive Officer, will be providing
a live presentation of the Group's recently announced interim results for the
six months ended 30 June 2024 via the Investor Meet Company platform, on
Thursday 3 October at 3pm BST.

 

The presentation is open to all existing and potential shareholders and will
be followed by a Q&A session. Questions can be submitted ahead of the
event through the Investor Meet Company dashboard up until 9am BST on
Wednesday 2 October 2024, or at any time during the live presentation.

 

To sign up to Investor Meet Company for free and to register for Arecor's
presentation, please visit:

https://www.investormeetcompany.com/companies/arecor-therapeutics-plc
(https://www.investormeetcompany.com/companies/arecor-therapeutics-plc)

 

Investors who already follow Arecor on the Investor Meet Company platform will
automatically be invited to the event.

 

 

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                           www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer          Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com (mailto:info@arecor.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)    Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)
 Nigel Barnes, Satheesh Nadarajah                  Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville       Tel: +44 (0) 20 3709 5700

                                                   Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUNRARSVUKUUR